To include your compound in the COVID-19 Resource Center, submit it here.

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

By teaming with Astellas to develop bispecifics for immuno-oncology, CytomX has struck its first major partnership in two-and-a-half years, giving its shares a much-needed boost after a prolonged slump in 2018-19.

Astellas Pharma Inc. (Tokyo:4503) is paying $80 million up front to discover and develop

Read the full 445 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE